NOM
NOM Finance, the private equity and venture capital branch of NV NOM Investerings- En Ontwikkelingsmaatschappij voor Noord-Nederland, focuses on fostering the growth of businesses in Northern Netherlands, particularly in the provinces of Groningen, Friesland, and Drenthe. The firm specializes in investments across various sectors including agro and food, information technology, life sciences, cleantech, healthcare, and high-tech industries, while intentionally avoiding primary agriculture, retail, and regional services. NOM Finance provides funding for seed and startup ventures, expansion, restructuring, and management buy-outs, typically investing between €0.5 million and €2.5 million in equity and mezzanine financing, as well as offering deferred loans ranging from €0.05 million to €1.5 million. The firm usually seeks minority stakes in its portfolio companies and aims for exits within five to seven years. Established in 1974 and headquartered in Groningen, NOM Finance plays a vital role in supporting entrepreneurs throughout the various stages of their businesses.
Flow is a FinTech startup focussed on money automation.Flow lets you automate transactions between your accounts. Based on triggers you can transfer your money automatically to the accounts you choose.
Detact Diagnostics B.V. engages in the development and testing of bacterial detection solutions for hospitals and healthcare institutions. It offers b-Swab, a bacterial detection system that enables hospital staff to determine bacterial presence on surface areas. The company was founded in 2014 and is based in Groningen, the Netherlands.
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.